| BioCardia Regains Full Compliance with Nasdaq Listing Requirements | 09/18 08:30 | globenewswire.com |
| BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 09/09 16:05 | globenewswire.com |
| BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family | 08/29 08:30 | globenewswire.com |
| FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment | 08/21 07:00 | globenewswire.com |
| BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript | 08/13 19:53 | seekingalpha.com |
| BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results | 08/13 16:30 | globenewswire.com |
| Bet on 5 Top-Ranked Stocks With Rising P/E | 08/12 09:01 | zacks.com |
| BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application | 07/17 07:00 | globenewswire.com |
| BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach | 06/07 07:00 | globenewswire.com |
| BioCardia Announces Reverse Stock Split | 05/21 17:00 | globenewswire.com |